{"id":"rabies-immune-globulin-human","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":{"setId":"f82880b8-998c-4659-8f20-6dcc81f258e9","title":"HYPERRAB (RABIES IMMUNE GLOBULIN (HUMAN)) INJECTION, SOLUTION [GRIFOLS USA, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This product contains immunoglobulin G (IgG) antibodies derived from human plasma of donors immunized against rabies virus. These antibodies bind to and neutralize rabies virus particles, preventing viral attachment and entry into nerve cells. It is administered as part of post-exposure prophylaxis (PEP) alongside rabies vaccine to provide immediate protection while the vaccine stimulates active immunity.","oneSentence":"Rabies immune globulin provides passive immunization by supplying human antibodies that neutralize rabies virus and prevent its progression to the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:11.224Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Post-exposure prophylaxis of rabies in non-immunized individuals following potential rabies virus exposure"}]},"trialDetails":[{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT07445815","phase":"PHASE2","title":"A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody","status":"NOT_YET_RECRUITING","sponsor":"Lanzhou Institute of Biological Products Co., Ltd","startDate":"2026-01-31","conditions":"Rabies (Healthy Volunteers)","enrollment":200},{"nctId":"NCT07399951","phase":"EARLY_PHASE1","title":"Washington University WU 409: Immune Responses to Rabies Vaccine.","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2023-07-18","conditions":"Healthy Participants","enrollment":30},{"nctId":"NCT03961555","phase":"PHASE2","title":"Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2019-09-03","conditions":"Rabies","enrollment":448},{"nctId":"NCT07342257","phase":"PHASE1","title":"SYN023 With Rabies Vaccine in Healthy Pediatric Subjects","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2024-11-30","conditions":"Rabies Post-exposure Prophylaxis","enrollment":108},{"nctId":"NCT05382650","phase":"","title":"Survey of Human Rabies Immune Globulin Safety in Children","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2023-02-22","conditions":"Rabies, Rabies Human, Rabies Virus Infection","enrollment":35},{"nctId":"NCT04478084","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-08-04","conditions":"Rabies (Healthy Volunteers)","enrollment":403},{"nctId":"NCT04594551","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-11","conditions":"Rabies (Healthy Volunteers)","enrollment":201},{"nctId":"NCT03965962","phase":"PHASE3","title":"Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-07-01","conditions":"Rabies (Healthy Volunteers)","enrollment":640},{"nctId":"NCT05846568","phase":"PHASE3","title":"Study to Evaluate GR1801's Efficacy and Safety","status":"COMPLETED","sponsor":"Genrix (Shanghai) Biopharmaceutical Co., Ltd.","startDate":"2022-10-21","conditions":"Rabies Post-exposure Prophylaxis","enrollment":1200},{"nctId":"NCT06548139","phase":"PHASE2","title":"Rabies mAb CBB 1 Combination Vaccine in Healthy People With Antibody Neutralization Activity and Safety Phase Clinical Trials","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2024-07-31","conditions":"Rabies Virus Infection","enrollment":120},{"nctId":"NCT05832073","phase":"EARLY_PHASE1","title":"Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1","status":"UNKNOWN","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2023-04-30","conditions":"Rabies Virus Infection","enrollment":152},{"nctId":"NCT04644484","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2020-09-23","conditions":"Rabies, Communicable Disease, Virus Diseases","enrollment":1000},{"nctId":"NCT05547815","phase":"PHASE4","title":"Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine","status":"COMPLETED","sponsor":"Changchun Zhuoyi Biological Co., Ltd","startDate":"2019-11-11","conditions":"Rabies, Antibody","enrollment":149},{"nctId":"NCT03145766","phase":"PHASE2","title":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-04-17","conditions":"Rabies Virus","enrollment":320},{"nctId":"NCT02040090","phase":"PHASE2, PHASE3","title":"Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Kamada, Ltd.","startDate":"2013-04","conditions":"Rabies","enrollment":118},{"nctId":"NCT04495569","phase":"PHASE1, PHASE2","title":"A Bridging Study of the SYN023 on Healthy Adult Subjects","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2019-02-26","conditions":"Communicable Disease Transmission, Zoonotic Disease, Rabies Human","enrollment":33},{"nctId":"NCT02956746","phase":"PHASE1, PHASE2","title":"A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines","status":"COMPLETED","sponsor":"Synermore Biologics Co., Ltd.","startDate":"2016-08","conditions":"Human Rabies","enrollment":164},{"nctId":"NCT01610362","phase":"NA","title":"Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2012-06","conditions":"Rabies","enrollment":50},{"nctId":"NCT03192371","phase":"PHASE4","title":"A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2018-02-15","conditions":"Virus Diseases","enrollment":""},{"nctId":"NCT02177032","phase":"PHASE3","title":"Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age","status":"COMPLETED","sponsor":"Novartis","startDate":"2014-06","conditions":"Rabies Infection","enrollment":885},{"nctId":"NCT02559921","phase":"PHASE2","title":"Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.","status":"COMPLETED","sponsor":"Beijing Chaoyang District Centre for Disease Control and Prevention","startDate":"2014-12","conditions":"Rabies","enrollment":300},{"nctId":"NCT02139657","phase":"PHASE1","title":"An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2014-03","conditions":"Rabies","enrollment":12},{"nctId":"NCT01228383","phase":"PHASE2","title":"Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-12","conditions":"Rabies","enrollment":240},{"nctId":"NCT00708084","phase":"PHASE2","title":"Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2008-05","conditions":"Rabies","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IMOGAM® Rabies-HT"],"phase":"marketed","status":"active","brandName":"Rabies immune globulin (human)","genericName":"Rabies immune globulin (human)","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Rabies immune globulin provides passive immunization by supplying human antibodies that neutralize rabies virus and prevent its progression to the central nervous system. Used for Post-exposure prophylaxis of rabies in non-immunized individuals following potential rabies virus exposure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}